Ambrisentan: new drug. Too risky in mildly symptomatic pulmonary hypertension.
(1) In patients with mildly symptomatic pulmonary hypertension (stage III), there is no firm evidence that ambrisentan reduces mortality or slows disease progression. In contrast, ambrisentan has frequent and sometimes serious adverse effects; (2) In patients whose physical activity is markedly restricted by pulmonary hypertension, it is better to continue using bosentan, with which we have far more experience.
D002986:Clinical Trials as Topic; D017277:Drug Approval; D005060:Europe; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D009965:Orphan Drug Production; D010666:Phenylpropionates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011724:Pyridazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D010666:Phenylpropionates; D011724:Pyridazines